Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: A systematic review and meta …
Y Wang, T Zhang, Y Huang, W Li, J Zhao… - International Journal of …, 2022 - Elsevier
Purpose Consolidation durvalumab after chemoradiation therapy (CRT) has improved
patient outcomes in stage III non-small cell lung cancer (NSCLC) since the practice …
patient outcomes in stage III non-small cell lung cancer (NSCLC) since the practice …
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology
R Jamal, M Messaoudene, M de Figuieredo… - Seminars in …, 2023 - Elsevier
The gut microbiota has rapidly emerged as one of the “hallmarks of cancers” and a key
contributor to cancer immunotherapy. Metagenomics profiling has established the link …
contributor to cancer immunotherapy. Metagenomics profiling has established the link …
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a
standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and …
standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and …
A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung …
Introduction For unresectable stage III non-small cell lung cancer (NSCLC), the standard
therapy consists of chemoradiotherapy (CRT) followed by durvalumab maintenance for …
therapy consists of chemoradiotherapy (CRT) followed by durvalumab maintenance for …
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy …
G Saito, Y Oya, Y Taniguchi, H Kawachi, F Daichi… - Lung Cancer, 2021 - Elsevier
Objectives The incidence of real-world pneumonitis and durvalumab rechallenge during
chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is …
chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is …
Incidence and risk factors of symptomatic radiation pneumonitis in non–small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation …
T Shintani, N Kishi, Y Matsuo, M Ogura, T Mitsuyoshi… - Clinical Lung Cancer, 2021 - Elsevier
Introduction Data on the risk factors for symptomatic radiation pneumonitis (RP) in non–
small-cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) …
small-cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) …
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
Y Landman, O Jacobi, N Kurman, O Yariv… - …, 2021 - Taylor & Francis
The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy
(CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our …
(CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our …
Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab
RW Gao, CN Day, A Bush, AC Amundson… - Lung Cancer, 2022 - Elsevier
Objectives The incidence and predictors of pneumonitis for patients with unresectable,
locally advanced non-small cell lung cancer (NSCLC) in the era of consolidation …
locally advanced non-small cell lung cancer (NSCLC) in the era of consolidation …
Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta …
Y Zhang, Y Tian, L Zheng, X Sun, Z Zhao… - Frontiers in …, 2023 - frontiersin.org
Background: The current review aimed to pool real-world evidence on the efficacy and
toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer …
toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer …
Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer
T Xu, L Wu, S Gandhi, W Jing, QN Nguyen… - Radiotherapy and …, 2022 - Elsevier
Purpose We compared treatment-related pulmonary adverse events (TRPAE), progression-
free survival (PFS), and overall survival (OS) among locally advanced non-small cell lung …
free survival (PFS), and overall survival (OS) among locally advanced non-small cell lung …